欢迎来到期刊吧-专注期刊发表！
关于我们联系我们发表流程付款方式医学sci转让留言板
您的位置： 首页 > 国外期刊 > Advances in Breast Cancer Research

Body Mass Index and Breast Cancer Risk: A Retrospective Multi-Institutional Analysis in Saudi Arabia

Advances in Breast Cancer Research
Vol.2No.1(2013), Article ID:27257,4 pages DOI:10.4236/abcr.2013.21002

Volker Rudat1*, Nuha Birido2, Saleh Tuwaijri3, Mousa A. Al-Abbadi4

1Department of Radiation Oncology, Saad Specialist Hospital, Al Khobar, KSA

2Department of Surgery, King Fahad Specialist Hospital, Dammam, KSA

3Saad Research & Development Center, Saad Specialist Hospital, Al Khobar, KSA

4Department of Pathology and Laboratory Medicine, King Fahad Specialist Hospital, Dammam, KSA

Email: *vrudat@saadmedical.com

Received December 4, 2012; revised January 6, 2013; accepted January 14, 2013

Keywords: Breast Cancer; Body Mass Index; Adolescent; Female; Saudi Arabia

ABSTRACT

Background: The purpose of this study was to evaluate the association between the body mass index (BMI) of breast cancer patients and non-cancer females of the Eastern Province of Saudi Arabia. Methods: The weight, height and age was obtained from the patient records of 706 newly diagnosed breast cancer patients and of 20,872 non-cancer female patients who consulted the two largest hospitals in the Eastern Province of Saudi Arabia between 2006 and 2012. Factorial analysis of variance (ANOVA) was used to assess the association between the BMI, age and breast cancer status. Results: The mean BMI of the non-cancer females was 29.4 and the percentage of obese patients of the different age groups ranged from 23.9% to 66.5%. The BMI increased significantly with age. The ANOVA revealed that breast cancer patients older than 50 years had a significantly lower BMI compared to their non-cancer counterparts (p = 0.01). Conclusion: Our data confirm the high BMI of the Saudi Arabian female population. The reason for our finding of a lower BMI of postmenopausal breast cancer patients compared to their non-cancer counterparts is unclear. Future studies are warranted to assess the impact of possible confounding factors on the association between obesity and breast cancer risk. An interesting factor to investigate in future studies would particularly be the use of the anti-diabetic and cancer-protective drug metformin considering that diabetes mellitus is endemic in Saudi Arabia with a prevalence of 30%.

1. Introduction

The prevalence of obesity has been rapidly increasing in many middle-income and low-income countries. At present more than 1.3 billion people globally are estimated to be overweight or obese [1].

Obesity is a generally recognized risk factor for metabolic syndrome, type II diabetes mellitus, cardiovascular disease and several cancers including breast cancer [2]. The risk of developing postmenopausal breast cancer is increased by 30% - 50% in obese women [2]. Furthermore, obesity has been shown to be associated with a poorer prognosis in breast cancer patients regardless of the menopausal status [3]. A recent systematic review showed an increased risk of 33% for both breast cancerspecific death and death from all causes in obese women compared to lean women [4].

Breast cancer is the most common malignancy in Saudi Arabia. It amounts to 26% of all newly diagnosed cancers in women and to 13.8% in the combined genders. With an age-standardized rate of 21.6/100,000 for female population, the incidence of breast cancer in Saudi Arabia is lower than that in the United States (124/100,000) [5,6]. About 25% of the breast cancer patients in Saudi Arabia are younger than 40 years of age and the mean age at diagnosis is 47 years [6-8]. The high percentage of young breast cancer patients in Saudi Arabia may at least in part be explained by the young age structure of the Saudi Arabian population where approximately 50% of the females are younger than 20 years of age [6]. In contrast, in the United States about 7% of breast cancer patients are younger than 40 years [9], and the median age at diagnosis is 61 years.

While the prevalence of obesity in Saudi Arabia has been thoroughly investigated, no data of the BMI of Saudi Arabian breast cancer patients are available according to a MEDLINE (PubMed) search.

The goal of this study was to evaluate the BMI of breast cancer patients and non-cancer females in Saudi Arabia, and to compare the BMI with published corresponding data from the United States.

2. Methods

Patient records were reviewed of patients who consulted Saad Specialist Hospital and King Fahad Specialist Hospital in Dammam between 2006 and 2012. The Saad Specialist Hospital and King Fahad Specialist Hospital in Dammam are the two largest tertiary hospitals in the Eastern province of Saudi Arabia. Eligible for the study were non-pregnant female patients of Saudi Arabian nationality with a minimum age of 20 years, a tissue biopsy-proven new diagnosis of invasive breast cancer (“breast cancer patients”), or any other diagnosis apart from cancer or other malignant tumors (“non-cancer females”). The height, weight and age at the time of diagnosis of invasive breast cancer, or at the first consultation in the hospital of non-cancer patients, respectively, were anonymously transferred into a database. The weight and height were routinely assessed and documented in the patient records in both hospitals. The BMI was calculated as weight·kg/height·m2.

Data of 706 newly diagnosed female breast cancer patients and of 20,872 female non-cancer patients were collected and analyzed. Of the non-cancer patients, the data were obtained from the Departments of Gynecology (29.4%), Dermatology (10.1%), Primary Care (6.5%), and in smaller percentages from other departments.

The study was approved by the Institutional Review Boards of both hospitals.

Statistical Analysis

Descriptive statistics of the BMI of breast cancer and non-cancer female patients of different age groups were calculated. The difference between the BMI of breast cancer patients and non-cancer females of different age groups was assessed for statistical significance using the two-tailed student t-test. For the student t-tests, no correction for multiple testing was used, and the corresponding p-values have to be considered descriptive.

The association between BMI, age and breast cancer status was assessed using factorial analysis of variance (ANOVA). For the ANOVA, the log-transformed BMI was used as continuous dependent variable and the age and breast cancer status (breast cancer versus non-cancer) as categorical variables.

3. Results

Our data show that the BMI significantly increases with age, and that the percentage of obese women is high in all examined age groups (range, 23.9% to 66.5%; Figure 1, Tables 1 and 2). Compared with recent data from the United States [10], the prevalence of different grades of obesity among Saudi Arabian women was markedly higher in the age groups older than 40 years (factor 1.4 - 1.7) and comparable in the younger age group of 20 - 39 years (Table 3).

The ANOVA and the student t-test showed that Saudi Arabian breast cancer patients older than 50 years had a significantly lower BMI than their non-cancer counterparts. No difference of the BMI was found for women younger than 50 years (Figure 1, Tables 1 and 2).

4. Discussion

Our data confirm the high prevalence of obesity in the Saudi Arabian female population. Compared to the United States, the prevalence of obesity was higher in Saudi Arabian women older than 40 years and comparable in women younger than 40 years.

A surprising finding of our analysis was the statistically significant lower BMI of postmenopausal breast cancer patients compared to their non-cancer counterparts. It is generally recognized that the risk of postmenopausal breast cancer increases with increasing BMI [11,12] and therefore the opposite result was expected.

The reason for this unexpected finding is unclear. Due to limitations of a retrospective study and the relatively low number of breast cancer patients investigated in our study (n = 706; non-cancer females, n = 20,872) a statistical artifact or bias cannot be fully excluded. However, the BMI of non-cancer females in our study was in full agreement with recently published reports evaluating the BMI of the Saudi Arabian population, suggesting that our data are representative [13,14]. On the other hand, there are several factors that may mask or alter the expected relation between high BMI and increased postmenopausal breast cancer risk. In studies where the use of

Figure 1. Association between BMI and age of newly diagnosed female breast cancer patients and female non-cancer patients. The squares and vertical lines represent the mean and standard deviation of the log-transformed BMI.

Table 1. Body Mass Index of breast cancer patients at time of diagnosis and of non-cancer patients stratified by age.

Abbreviations: BMI: Body mass index; SD: Standard deviation;*Student t-test.

Table 2. Association between the body mass index, age, and breast cancer status. Results of the Analysis of Variance (ANOVA).

Table 3. Comparison of different grades of obesity of American women (Flegal et al. 2012, n = 6074, [10]) and noncancer patients of this study (n = 20,872).

hormone replacement therapy (HRT) was considered as predictive factor in the statistical analysis the risk of developing breast cancer was only increased in the subgroup of postmenopausal women who have never received HRT [15-18]. Type II diabetes mellitus has been shown to be associated with an increased risk of postmenopausal breast cancer [19,20] and a worse prognosis [21], and insulin use with an increased breast cancer incidence [22,23] and recurrence [21,24]. Another interesting factor currently in the scientific focus is the drug “metformin”. Metformin is the drug of first choice in the management of type 2 diabetes, in particular in overweight and obese patients [25]. Recent studies have shown that met formin significantly reduces breast cancer incidence [26-28]. With a prevalence of 30%, diabetes mellitus type 2 is “endemic” in Saudi Arabia [29]. It can be speculated that our observation of a significantly lower BMI of Saudi Arabian postmenopausal breast cancer patients may be due to the anti-cancer effect of metformin.

In conclusion, future studies are warranted to assess the impact of possible confounding factors on the association between obesity and breast cancer risk. Relevant factors like comorbidities (e.g. diabetes), medication use (e.g. metformin, insulin, HRT), race and ethnicity, and other factors should be carefully assessed in a time-dependent and exposure-related manner.

REFERENCES

  1. B. M. Popkin, “Understanding Global Nutrition Dynamics as a Step towards Controlling Cancer Incidence,” Nature Reviews Cancer, Vol. 7, No. 1, 2007, pp. 61-67. doi:10.1038/nrc2029
  2. E. E. Calle and R. Kaaks, “Overweight, Obesity and Cancer: Epidemiological Evidence and Proposed Mechanisms,” Nature Reviews Cancer, Vol. 4, No. 8, 2004, pp. 579-591. doi:10.1038/nrc1408
  3. A. R. Carmichael, “Obesity and Prognosis of Breast Cancer,” Obesity Reviews, Vol. 7, No. 4, 2006, pp. 333-340. doi:10.1111/j.1467-789X.2006.00261.x
  4. M. Protani, M. Coory and J. H. Martin, “Effect of Obesity on Survival of Women with Breast Cancer: Systematic Review and Meta-Analysis,” Breast Cancer Research and Treatment, Vol. 123, No. 3, 2010, pp. 627-635. doi:10.1007/s10549-010-0990-0
  5. National Cancer Institute, “Surveillance, Epidemiology and End Results (SEER) Program,” 2012. http://seer.cancer.gov/statfacts/html/breast.html#incidence-mortality
  6. H. S. Al-Eid, “Cancer Incidence and Survival Report Saudi Arabia 2007,” 2012. http://www.scr.org.sa/reports/SCR2007.pdf
  7. V. Rudat, I. Brune-Erbe, A. Noureldin, Z. Bushnag, N. Almuraikhi and S. Altuwaijri, “Epidemiology of Breast Cancer Patients at a Tertiary Care Center in the Eastern Province of Saudi Arabia,” Gulf Journal of Oncology, Vol. 1, No. 11, 2012, pp. 45-49.
  8. V. Rudat, H. El-Sweilmeen, E. Fadel, I. Brune-Erber, A. A. Nour, Z. Bushnag, N. Masri and S. Altuwaijri, “Age of 40 Years or Younger Is an Independent Risk Factor for Locoregional Failure in Early Breast Cancer: A Single-Institutional Analysis in Saudi Arabia,” Journal of Oncology, Vol. 2012, 2012, Article ID: 370385.
  9. C. K. Anders, R. Johnson, J. Litton, M. Phillips and A. Bleyer, “Breast Cancer before Age 40 Years,” Seminars in Oncology, Vol. 36, No. 3, 2009, pp. 237-249. doi:10.1053/j.seminoncol.2009.03.001
  10. K. M. Flegal, M. D. Carroll, B. K. Kit and C. L. Ogden, “Prevalence of Obesity and Trends in the Distribution of Body Mass Index among US Adults, 1999-2010,” JAMA, Vol. 307, No. 5, 2012, pp. 491-497. doi:10.1001/jama.2012.39
  11. A. R. Carmichael and T. Bates, “Obesity and Breast Cancer: A Review of the Literature,” Breast, Vol. 13, No. 2, 2004, pp. 85-92. doi:10.1016/j.breast.2003.03.001
  12. S. Loi, R. L. Milne, M. L. Friedlander, M. R. E. McCredie, G. G. Giles, J. L. Hopper and K.-A. Phillips, “Obesity and Outcomes in Premenopausal and Postmenopausal Breast Cancer,” Cancer Epidemiology Biomarkers & Prevention, Vol. 14, No. 7, 2005, pp. 1686-1691. doi:10.1158/1055-9965.EPI-05-0042
  13. N. A. Al-Baghli, A. J. Al-Ghamdi, K. A. Al-Turki, A. G. El-Zubaier, M. M. Al-Ameer and F. A. Al-Baghli, “Overweight and Obesity in the Eastern Province of Saudi Arabia,” Saudi Medical Journal, Vol. 29, No. 9, 2008, pp. 1319-1325.
  14. M. M. Al-Nozha, Y. Y. Al-Mazrou, M. A. Al-Maatouq, M. R. Arafah, M. Z. Khalil, N. B. Khan, K. Al-Marzouki, M. A. Abdullah, A. H. Al-Khadra, S. S. Al-Harthi, et al., “Obesity in Saudi Arabia,” Saudi Medical Journal, Vol. 26, No. 5, 2005, pp. 824-829.
  15. H. S. Feigelson, C. R. Jonas, L. R. Teras, M. J. Thun and E. E. Calle, “Weight Gain, Body Mass Index, Hormone Replacement Therapy, and Postmenopausal Breast Cancer in a Large Prospective Study,” Cancer Epidemiology, Biomarkers & Prevention, Vol. 13, No. 2, 2004, pp. 220- 224. doi:10.1158/1055-9965.EPI-03-0301
  16. C. Schairer, J. Lubin, R. Troisi, S. Sturgeon, L. Brinton and R. Hoover, “Menopausal Estrogen and EstrogenProgestin Replacement Therapy and Breast Cancer Risk,” JAMA, Vol. 283, No. 4, 2000, pp. 485-491. doi:10.1001/jama.283.4.485
  17. Collaborative Group on Hormonal Factors in Breast Cancer, “Breast Cancer and Hormone Replacement Therapy: Collaborative Reanalysis of Data from 51 Epidemiological Studies of 52,705 Women with Breast Cancer and 108,411 Women without Breast Cancer,” Lancet, Vol. 350, No. 9084, 1997, pp. 1047-1059. doi:10.1016/S0140-6736(97)08233-0
  18. L. M. Morimoto, E. White, Z. Chen, R. T. Chlebowski, J. Hays, L. Kuller, A. M. Lopez, J. Manson, K. L. Margolis, P. C. Muti, et al., “Obesity, Body Size, and Risk of Postmenopausal Breast Cancer: The Women’s Health Initiative (United States),” Cancer Causes Control, Vol. 13, No. 8, 2002, pp. 741-751. doi:10.1023/A:1020239211145
  19. S. C. Larsson, C. S. Mantzoros and A. Wolk, “Diabetes Mellitus and Risk of Breast Cancer: A Meta-Analysis,” International Journal of Cancer, Vol. 121, No. 4, 2007, pp. 856-862. doi:10.1002/ijc.22717
  20. L. Vona-Davis and D. P. Rose, “Type 2 Diabetes and Obesity Metabolic Interactions: Common Factors for Breast Cancer Risk and Novel Approaches to Prevention and Therapy,” Current Diabetes Reviews, Vol. 8, No. 2, 2012, pp. 116-130. doi:10.2174/157339912799424519
  21. K. S. Peairs, B. B. Barone, C. F. Snyder, H. C. Yeh, K. B. Stein, R. L. Derr, F. L. Brancati and A. C. Wolff, “Diabetes Mellitus and Breast Cancer Outcomes: A Systematic Review and Meta-Analysis,” Journal of Clinical Oncology, Vol. 29, No. 1, 2011, pp. 40-46. doi:10.1200/JCO.2009.27.3011
  22. M. E. Del Giudice, I. G. Fantus, S. Ezzat, G. McKeown- Eyssen, D. Page and P. J. Goodwin, “Insulin and Related Factors in Premenopausal Breast Cancer Risk,” Breast Cancer Research and Treatment, Vol. 47, No. 2, 1998, pp. 111-120. doi:10.1023/A:1005831013718
  23. I. Wolf, S. Sadetzki, R. Catane, A. Karasik and B. Kaufman, “Diabetes Mellitus and Breast Cancer,” The Lancet Oncology, Vol. 6, No. 2, 2005, pp. 103-111. doi:10.1016/S1470-2045(05)01736-5
  24. K. Erickson, R. E. Patterson, S. W. Flatt, L. Natarajan, B. A. Parker, D. D. Heath, G. A. Laughlin, N. Saquib, C. L. Rock and J. P. Pierce, “Clinically Defined Type 2 Diabetes Mellitus and Prognosis in Early-Stage Breast Cancer,” Journal of Clinical Oncology, Vol. 29, No. 1, 2011, pp. 54-60. doi:10.1200/JCO.2010.29.3183
  25. D. M. Nathan, J. B. Buse, M. B. Davidson, E. Ferrannini, R. R. Holman, R. Sherwin and B. Zinman, “Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes,” Diabetes Care, Vol. 32, No. 1, 2009, pp. 193-203. doi:10.2337/dc08-9025
  26. R. T. Chlebowski, A. McTiernan, J. Wactawski-Wende, J. E. Manson, A. K. Aragaki, T. Rohan, E. Ipp, V. G. Kaklamani, M. Vitolins, R. Wallace, et al., “Diabetes, Metformin, and Breast Cancer in Postmenopausal Women,” Journal of Clinical Oncology, Vol. 30, No. 23, 2012, pp. 2844-2852. doi:10.1200/JCO.2011.39.7505
  27. H. Noto, A. Goto, T. Tsujimoto and M. Noda, “Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-Analysis,” PLoS One, Vol. 7, No. 3, 2012, Article ID: e33411. doi:10.1371/journal.pone.0033411
  28. N. F. Col, L. Ochs, V. Springmann, A. K. Aragaki and R. T. Chlebowski, “Metformin and Breast Cancer Risk: A Meta-Analysis and Critical Literature Review,” Breast Cancer Research and Treatment, Vol. 135, No. 3, 2012, pp. 639-646. doi:10.1007/s10549-012-2170-x

NOTES

*Corresponding author.

上一篇:Combined Patients and Medical 下一篇:Diagnosis Error: Carcinoma or

我要分享到：